Back to results
US 10,648,040 B2Granted
Immune gene signatures in treating breast cancer
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsJames J. Mulé, Domenico Coppola, Timothy J. Yeatman, Audrey Loboda, Michael V. Nebozhyn
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for treating subjects with breast cancer, based on tumor expression levels of chemokines.
Claims15
A method of treating a subject who has breast cancer, the method comprising:
- obtaining cells from the breast cancer;
- determining gene expression levels of chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5, CCL8, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18), CCL19, CCL21, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, CXCL11, and CXCL13 in the breast cancer cells;
- comparing the breast cancer gene expression levels to reference gene expression levels;
- identifying a subject who has breast cancer gene expression levels above the reference gene expression levels;
- and
- administering a treatment comprising cyclophosphamide to a subject who has breast cancer gene expression levels above the reference gene expression levels.
3 more elements
A method of treating a subject who has breast cancer, the method comprising:
- obtaining cells from the breast cancer;
- determining gene expression levels of CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, and CXCL13 in the breast cancer cells;
- comparing the breast cancer gene expression levels to reference gene expression levels;
- identifying a subject who has breast cancer gene expression levels above the reference gene expression levels;
- and
- administering a treatment comprising anti-interleukin-2R immunotoxin to a subject who has breast cancer gene expression levels above the reference gene expression levels.
3 more elements
A method of treating a subject who has breast cancer, the method comprising:
- obtaining cells from the breast cancer;
- determining gene expression levels of chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5, CCL8, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18), CCL19, CCL21, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, CXCL11, and CXCL13 in the breast cancer cells;
- comparing the breast cancer gene expression levels to reference gene expression levels;
- identifying a subject who has breast cancer gene expression levels above the reference gene expression levels;
- and
- administering a treatment comprising an anti-cancer antibody selected from the group consisting of anti-CD137, anti-programmed death-1 receptor (PD1), and anticytotoxic T-lymphocyte antigen-4 (CTLA-4), to a subject who has breast cancer gene expression levels above the reference gene expression levels.
3 more elements
Dependencies are inferred from the claim text.